8 terminated. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 2 | Terminated 2 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas SPH4336 - Liposarcoma, Dedifferentiated | Phase 2 | Terminated | Shanghai Pharma Biotherapeutics USA Inc. | 14 | 2023-08-31 | 2025-06-13 |
| TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma TQB3616 capsule, TQB3616 placebo - Dedifferentiated Liposarcoma | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 26 | 2022-08-08 | 2025-11-21 |
| ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma ATX-101 - Leiomyosarcoma, Liposarcoma | Phase 2 | Terminated | Benjamin Izar | 4 | 2022-01-11 | 2023-12-06 |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma | Phase 2 | Terminated | Pfizer | 76 | 2021-06-22 | 2024-12-11 |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 35 | 2017-09-28 | 2022-04-29 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 2 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 89 | 2015-04-29 | 2020-07-07 |
| Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial plitidepsin - Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma | Phase 2 | Terminated | Institut BergoniƩ | 24 | 2012-02-01 | 2021-01-25 |
| Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma nelfinavir mesylate, biopsy, laboratory biomarker analysis - Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | City of Hope Medical Center | 29 | 2006-03-01 | 2015-04-01 |
Leiomyosarcoma (3) · Sarcoma (3) · Dermatofibrosarcoma (1) · Hemangiosarcoma (1) · Liposarcoma, Myxoid (1) · Neoplasm Metastasis (1) · Recurrence (1) · Sarcoma, Synovial (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Adipose Tissue (8) · Neoplasms, Connective and Soft Tissue (8) · Sarcoma (5) · Neoplasms, Muscle Tissue (3) · Neoplasms, Connective Tissue (2) · Disease Attributes (1) · Fibrosarcoma (1) · Neoplasms, Fibrous Tissue (1) · Neoplasms, Vascular Tissue (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Biopsy (1) · Blotting, Western (1) · Doxorubicin (1) · Gene Expression Profiling (1) · Immunoenzyme Techniques (1) · Nelfinavir (1) · Reverse Transcriptase Polymerase Chain Reaction (1) · TTI-621 (1) · Trabectedin (1) · atezolizumab (1) · avelumab (1) · plitidepsin (1)
Benjamin Izar (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Institut BergoniĆ© (1) · Pfizer (1) · Shanghai Pharma Biotherapeutics USA Inc. (1)
United States (6) · China (1) · France (1)
Antoine Italiano, MD (1) · Benjamin Izar, MD (1) · Kenneth W Locke, PhD (1) · Seth Pollack (1) · Warren Chow (1)
PMID 26041763, PMID 34260265, PMID 39034053
P30CA015704 (1)